Comparison of the Pharmacokinetic (PK) and Pharmacodynamic (PD) Biosimilarity of Insulin Aspart 30 Injections After Single-Dose Subcutaneous Administration to Healthy Volunteers

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The present study is designed to compare the pharmacokinetic, pharmacodynamic and safety characteristics of UBLIN 30® (test product) and NovoMix®30 (reference product) in healthy male participants. The treatment consists of one single dose of the test or reference product, administered during each of the two study periods, separated by 7 days between dosing. A total of 52 participants will be enrolled in this trial and randomized in a 1:1 ratio into two groups (A/B), stratified by race (Asian, non-Asian).
Epistemonikos ID: e8af84a457e15324382644beb4927c0c1cbde3e9
First added on: Oct 16, 2026